Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu C, Hough D, Stevens RM, Schett G.

Ann Rheum Dis. 2014 Jun;73(6):1020-6. doi: 10.1136/annrheumdis-2013-205056.

2.

Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.

Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Hochfeld M, Teng LL, Schett G, Lespessailles E, Hall S.

J Rheumatol. 2015 Mar;42(3):479-88. doi: 10.3899/jrheum.140647.

3.

Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.

Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, Hu C, Stevens R, de Vlam KL.

Arthritis Rheum. 2012 Oct;64(10):3156-67. doi: 10.1002/art.34627.

4.

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.

Cutolo M, Myerson GE, Fleischmann RM, Lioté F, Díaz-González F, Van den Bosch F, Marzo-Ortega H, Feist E, Shah K, Hu C, Stevens RM, Poder A.

J Rheumatol. 2016 Sep;43(9):1724-34. doi: 10.3899/jrheum.151376.

PMID:
27422893
6.

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).

Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P.

Ann Rheum Dis. 2016 Jun;75(6):1065-73. doi: 10.1136/annrheumdis-2015-207963.

7.
8.

Apremilast: A Review in Psoriasis and Psoriatic Arthritis.

Deeks ED.

Drugs. 2015 Aug;75(12):1393-403. doi: 10.1007/s40265-015-0439-1. Review.

PMID:
26220911
9.

An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.

Betts KA, Griffith J, Friedman A, Zhou ZY, Signorovitch JE, Ganguli A.

Curr Med Res Opin. 2016;32(4):721-9. doi: 10.1185/03007995.2016.1140026. Review.

PMID:
26743448
10.

Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.

Genovese MC, Jarosova K, Cieślak D, Alper J, Kivitz A, Hough DR, Maes P, Pineda L, Chen M, Zaidi F.

Arthritis Rheumatol. 2015 Jul;67(7):1703-10. doi: 10.1002/art.39120.

11.

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).

Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, Crowley J.

J Am Acad Dermatol. 2016 Jan;74(1):134-42. doi: 10.1016/j.jaad.2015.09.001.

12.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).

Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE.

J Am Acad Dermatol. 2015 Jul;73(1):37-49. doi: 10.1016/j.jaad.2015.03.049.

13.

Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.

Haber SL, Hamilton S, Bank M, Leong SY, Pierce E.

Ann Pharmacother. 2016 Apr;50(4):282-90. doi: 10.1177/1060028015627467. Review.

PMID:
26783350
14.
15.

Drug safety evaluation of apremilast for treating psoriatic arthritis.

Busa S, Kavanaugh A.

Expert Opin Drug Saf. 2015 Jun;14(6):979-85. doi: 10.1517/14740338.2015.1031743. Review.

PMID:
25827658
16.

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM.

Lancet. 2012 Aug 25;380(9843):738-46. doi: 10.1016/S0140-6736(12)60642-4.

PMID:
22748702
17.

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).

Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB.

Br J Dermatol. 2015 Dec;173(6):1387-99. doi: 10.1111/bjd.14164.

PMID:
26357944
18.

Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis.

[No authors listed]

Prescrire Int. 2016 Jun;25(172):149-51. Review.

PMID:
27486641
19.

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).

Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J.

Arthritis Rheum. 2005 Apr;52(4):1227-36. Erratum in: Arthritis Rheum. 2005 Sep;52(9):2951.

20.

Apremilast for the treatment of psoriatic arthritis.

Souto A, Gómez-Reino JJ.

Expert Rev Clin Immunol. 2015;11(12):1281-90. doi: 10.1586/1744666X.2015.1102057. Review.

PMID:
26503917
Items per page

Supplemental Content

Support Center